Compare Hims and Hers Health Inc (HIMS) vs L3Harris Technologies Inc (LHX) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported 2025 revenue of $2.35 billion and net income of $128.37 million, though 2026 projections indicate a net loss. Recent news highlights executive departures and anticipation for Q2 2026 earnings on August 10, 2026.

The investment outlook is cautiously optimistic, supported by a 35% analyst buy rating and a $33.57 consensus price target. Key opportunities include growth in the weight-loss drug segment and international expansion. Risks involve profitability volatility, intense competition, and reliance on telehealth regulatory frameworks. The stock's valuation remains elevated with a P/E of 57.14, demanding strong future earnings growth to justify current levels.

LHX trades at $277.71, down 1.52% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $2.72 exceeding the $2.53 expectation. Recent contract wins, including a U.S. Space Force satellite award and U.S. Army communication system orders, highlight ongoing defense sector strength. The stock's valuation includes a P/E of 30.46 and a net income margin of 7.71% for 2025.

The outlook for LHX is positive, supported by a robust $40.7 billion backlog and 75% analyst buy ratings with a $367.50 consensus price target, implying significant upside. Key risks include execution on major contracts, defense budget fluctuations, and competitive pressures. The recent dividend of $1.25 per share underscores financial health, but investors should monitor debt levels and geopolitical factors affecting defense spending.